Zevra Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
Zevra Therapeutics, Inc. (ZVRA) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 1.54 million shares for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2025-08-12
- Zevra Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2025-06-30 was 1.54M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month |
|---|---|---|
| 2025-06-30 | 1.54M shares 10-Q · filed 2025-08-12 | 1.62M shares 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |